hepatitis B surface antigen vaccine
hepatitis B surface antigen vaccine: sourced relationships with 1 company · 2 clinical trials tracked.
hepatitis B surface antigen vaccine evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could hepatitis B surface antigen vaccine → DVAX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) HIV Infection | Approved |
Clinical Trial Registry Records (2)
B-Enhancement of HBV Vaccination in Persons Living With HIV (BEe-HIVe): Evaluation of HEPLISAV-B
Primary endpoint: Percentage of Participants With Primary Seroprotection Response
Demonstration Project on Health Care Worker Protection Against Hepatitis B in Kalulushi District
Primary endpoint: Demonstrate attainment of protective Hepatitis B surface antibody (anti-HBs) levels in their serum
Frequently asked questions
Which companies have sourced relationships with hepatitis B surface antigen vaccine?
hepatitis B surface antigen vaccine has dated SEC/FDA relationship records for DYNAVAX TECHNOLOGIES CORP.
How many clinical trials involve hepatitis B surface antigen vaccine?
BioSniper tracks 2 clinical trials involving hepatitis B surface antigen vaccine.